Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $11.40 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $30.34.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.29, a 83.18% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $55.23, a 1055.44% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $7.42, a 20.13% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $9.29, a 86.52% decline from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $68.92, a 35.67% decline from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $107.13, a 29.15% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $11.40 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $30.34 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $7.42 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | $9.29 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $9.29 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $9.29 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $9.29 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | $68.92 10-K · filed 2024-03-12 | ||||
| 2023-09-30 | $70.32 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $67.78 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $55.23 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $107.13 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | $3.97 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $3.66 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $4.78 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $151.20 10-K · filed 2023-03-07 | $5.04 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $4.62 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $5.25 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $5.57 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $5.60 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $5.83 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $5.93 10-Q/A · filed 2020-08-31 | ||||
| 2020-03-31 | $6.42 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $7.10 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | $7.38 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $7.26 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $6.64 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $7.85 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $7.85 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $7.78 10-Q · filed 2018-08-08 | ||||
| 2018-03-31 | $7.28 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $6.53 10-K · filed 2019-03-12 | ||||
| 2017-09-30 | $6.62 10-Q · filed 2017-11-08 | ||||
| 2016-12-31 | $2.44 10-K · filed 2018-03-12 | ||||
| 2016-09-30 | $2.29 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $2.22 10-Q · filed 2016-08-12 | ||||
| 2016-03-31 | $2.55 10-Q · filed 2016-05-13 | ||||
| 2015-12-31 | $1.00 10-K · filed 2017-03-08 | ||||
| 2013-12-31 | $0.17 10-K · filed 2015-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |